Great interest has been shown in understanding the pathology of Gaucher disease (GD), due to the recently discovered genetic relationship with Parkinson's disease. For such studies, suitable animal models of GD are required. Chemical induction of GD by inhibition of acid β-glucosidase (GCase) using the irreversible inhibitor, conduritol B-epoxide (CBE), is particularly attractive, although few systematic studies examining the effect of CBE on development of symptoms associated with neurological forms of GD have been performed.
Introduction
Gaucher disease (GD), one of the most common lysosomal storage disorders (LSDs) (1) , is caused by mutations in GBA1 (2) , the gene encoding the lysosomal hydrolase, acid β-glucosidase (GCase). The resulting GCase deficiency causes accumulation of the glycosphingolipids (GSLs), glucosylceramide (GlcCer) and its deacylated form, glucosylsphingosine (GlcSph), within the lysosomes of macrophages and other cells. GD is classified into three types, with all three displaying hepatosplenomegaly, anemia, thrombocytopenia, leukopenia and bone involvement (3, 4) , with the neurological forms (nGD), type 2 (acute) and type 3 (chronic), displaying central nervous system (CNS) involvement in addition to systemic disease. The recently-discovered genetic association between mutations in GBA1 and Parkinson's disease (5) has significantly enhanced the visibility of GD and nGD research, and renders characterization of nGD animal models of critical importance. Currently, two kinds of nGD mice are available, namely genetic models (6) (7) (8) (9) (10) (11) (12) (13) (14) and a chemically-induced model. In Gba flox/flox ;nestin-Cre mice (15) , GCase deficiency is restricted to neurons and macroglia, with normal GCase activity in microglia, whereas K14-lnl/lnl mice develop a more rapidly-progressing neurological disease (15) . Both of these mice have proven useful in nGD research, but their limited life-spans and the severity of their symptoms restrict their usefulness. Injection with the irreversible GCase inhibitor, conduritol B-epoxide (CBE) (16) , has also proved of great use, particularly since CBE crosses the blood brain barrier (BBB) (17) . While CBE has been widely used, and increasingly so because of attention paid to the GD/Parkinson's disease enigma, its use has been somewhat erratic, inasmuch as different laboratories inject with different doses, at different ages and using different species of mice (Table 1) .
To determine the appropriateness of CBE as a means to induce GD, and to fully characterize its action, we now systematically inject different amounts of CBE into mice of This article is protected by copyright. All rights reserved.
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different ages, and demonstrate that pathology is very similar to the two genetic models discussed above. Moreover, characterization of mice injected with CBE provides novel mechanistic insight into disease pathology. We suggest that the CBE model, even though it has inherent limitations, as do all mouse models, is nevertheless a useful and rapid means to induce nGD. In addition, we demonstrate that cessation of CBE treatment can arrest some but not all symptoms of nGD, and discuss how this experimental approach could be used to test the efficacy of potential therapies. ;nestin-Cre mice, which served as healthy controls. Genotyping was performed by polymerase chain reaction. Mice with a mixed genetic background (C57BL6/J and CBA with further backcrossings with C57BL6/J; Jackson Laboratories, USA) were also injected with CBE; this mouse expresses Thy1-YFP-H in some cortical neurons (18 (Fig. 1A) . Interestingly, mice injected with 100 mg/kg CBE starting on day 15 lived considerably longer than mice injected from day 8 ( Fig. 1B) and showed less severe symptoms, suggesting a hitherto unappreciated effect of the age of the mice on the ability of CBE to induce nGD symptoms.
Materials and methods

Mice
GCase activity was measured in vitro in brain samples from CBE-treated mice. GCase activity was reduced by >90-95%, irrespective of the concentration of CBE injected (data not shown). We next measured levels of GlcCer and GlcSph accumulation using a new LC-ESI-MS/MS method (Duan et al., submitted for publication) that allows separation of hexosylsphingosine species into GlcSph and galactosylsphingosine (GalSph). GlcCer and GlcSph levels increased linearly with CBE concentration ( Fig. 1C ; r 2 of 0.95 and 0.96, respectively). It should be noted that GlcSph levels in control mice (~0.2 ± 0.1 pmol/mg tissue) were close to the limit of detection, whereas GlcCer levels were significantly higher in control mice (~35 ± 5.7 pmol/mg tissue). A correlation was also observed between the average day of death of the mice and GlcCer levels (r 2 = 0.91), and to a somewhat lower extent to GlcSph levels (r 2 =0.83). Levels of GlcCer (338 ± 74 pmol/mg tissue) and GlcSph (28 ± 12 pmol/mg tissue) in 21-day old Gba flox/flox ;nestin-Cre mouse were similar to levels observed in mice injected with >50 mg/kg body weight CBE; since GCase activity is only defective in cells of neuronal origin in Gba flox/flox ;nestin-Cre mice, this suggests even higher levels of accumulation in cells defective in GCase. Note that no significant changes were observed in either galactosylceramide (GalCer) or GalSph levels (Fig. 1C) .
To further dissect changes in sphingolipid levels, the N-acyl chain composition of GlcCer was analyzed. Normal brain tissue contains particularly high levels of C18-and C24:1-sphingolipids (25) , and as expected, this was the case in C57BL/6 mice injected with PBS ( Fig. 1D and Table S2 ). However, the higher the CBE dose, the greater the increase in the proportion of C18:0-GlcCer and C18:1-GlcCer versus total GlcCer (C18:0-GlcCer was 85% of total GlcCer upon injection of 100 mg CBE/kg body weight, compared to 68% using 25 mg CBE/kg body weight), which were elevated at the expense of GlcCer with longer acyl chains. Likewise, the acyl chain composition of Gba flox/flox ;nestin-Cre mouse was biased towards C18-GlcCer; similar results have been obtained in other nGD mouse models (26) .
Since C18-GlcCer is most abundant in neurons (27) , this data supports our previous finding using electron microscopy that significant levels of GlcCer accumulate in nestin-expressing cells (i.e. neurons and astroglia) in nGD mouse brain (8) . Finally, we compared GlcCer levels in mice injected for 10 days with 100 mg/kg body weight CBE starting on day 8 vs. day 15.
Significantly lower levels of both of these lipids were detected in the latter (Fig. 1E) , consistent with data showing that CBE is less effective in generating nGD symptoms when injected into slightly older mice (Fig. 1A, B ).
Biochemical and genetic profile of CBE treated mice
We have recently shown changes in levels of a number of inflammatory and other gene transcripts in Gba flox/flox ;nestin-Cre mice ((6, 7, 28) and unpublished data), and we now compare these changes with those observed in mice injected with CBE. We next performed a gene array study using the cortex of C57BL/6 mice injected with 25 mg/kg CBE from days 8 to 18. Vitner et al., submitted for publication). The number of genes increased in Gba flox/flox ;nestinCre mice was ~4 fold higher than in CBE-treated mice (Fig. 2B) , presumably because the disease in the CBE model is less severe at this stage; however, striking similarities were found. Thus, 144 genes were up-regulated in CBE-treated mice, of which 120 were also upregulated in Gba flox/flox ;nestin-Cre mice. Common up-regulated genes were next subjected to pathway analysis. Among these genes, inflammatory pathways such as complement system and the interferon signaling pathway, were highly enriched (Fig. 2C) . Notably, inflammatory genes were up-regulated in both models even though, as opposed to the CBE model, the Gba flox/flox ;nestin-Cre mouse does not accumulate GlcCer and GlcSph in microglia.
Interestingly, many of the genes that were up-regulated only in the Gba flox/flox ;nestin-Cre mouse belong to the same pathways as altered in mice injected with CBE. However, there
were several pathways that were enriched only in the Gba flox/flox ;nestin-Cre mice, including death receptor signaling ( Fig. S1 ), which may be related to neuronal loss observed in the This article is protected by copyright. All rights reserved.
Accepted Article
Gba flox/flox ;nestin-Cre at day 14 compared to the little neuronal loss observed in mice injected with CBE at day 18.
We next examined the regional selectivity of pathological changes in CBE-treated mice compared to Gba flox/flox ;nestin-Cre mice. Mice were injected with 37.5 mg/kg body weight CBE starting on post-natal day 8, followed by examination of MAC2 immunoreactivity at various times (7) . A low level of MAC2 immunoreactivity was observed on day 14 ( Fig. 3A) , but by day 18, microglia activation was evident in many brain areas, though predominantly in the brain stem and in cortical layer V. By 25 days, MAC2
immunoreactivity was widespread. Interestingly, the brain stem displayed much stronger MAC2 immunoreactivity in CBE-treated mice than Gba flox/flox ;nestin-Cre mice. As in Gba flox/flox ;nestin-Cre mice, a number of brain areas did not show neuropathology ( Table 2) .
We also analyzed pathology in the K14-lnl/lnl mouse, as these mice accumulate
GlcCer in all cell types in the brain (15) (Fig. 3B ). The highest level of MAC2 staining was observed in the K14-lnl/lnl mouse, although previous observations (15) suggested more extensive MAC2 labeling in Gba flox/flox ;nestin-Cre mice; it should be noted that the K14-lnl/lnl mice used in the current study were backcrossed onto an outbred CD1 background, whereas in the original study mice were generated on a C57BL/6 background. The main differences between the three mice was that K14-lnl/lnl mice showed extensive MAC2 labeling throughout the brain, and most prominently in the brain stem, as also observed in mice injected with CBE ( Table 2) .
Use of the CBE model in determining pathological pathways and for testing therapeutic windows
We now took advantage of the accessibility and flexibility of inducing CBE in mice to further examine the temporal sequence of events leading to neuronal cell death and neuroinflammation, and to examine putative therapeutic windows upon cessation of CBE This article is protected by copyright. All rights reserved. Another advantage of the CBE model compared to genetic models is that CBE treatment can be stopped at various times, allowing examination of the reversibility of the pathology. We injected mice from a mixed genetic background (C57BL6/J and CBA) (18) with 100 mg/kg of CBE from post-natal day 15 for various lengths of time, followed by cessation of CBE treatment. The first group of mice was injected with CBE from days 15-35, with CBE treatment stopped in some mice on day 25 (Fig. 5 ). In the second group, mice were injected with CBE from days 15-48, with CBE treatment stopped in some mice on day 25, allowing a longer period of recovery after cessation of CBE treatment (Fig. 5) . The third group of mice was injected with CBE for a longer period, from days 15-40, with CBE treatment stopped in some mice on day 30 (Fig. 6 ). The last group of mice was injected with CBE from days 15-74, with CBE treatment stopped in some mice on day 30 (Fig. 6 ).
In the first group, no effect on symptoms (i.e. body weight) was detected by day 24, but mice treated continuously with CBE lost considerable weight by day 35. Upon cessation of CBE treatment on day 24, mice gained weight similarly to control mice (Fig. 5A ). Despite the lack of overt signs, a significant number of MAC2-positive cells were detected in CBEtreated mice on day 25, although considerably fewer MAC2-positive cells were seen on day
This article is protected by copyright. All rights reserved.
Accepted Article 35 when CBE treatment was stopped on day 25 (Fig. 5B ). Mice injected with CBE from days 15-25 displayed impaired motor behavior (Fig. 5C) . Thus, the latency to fall was reduced by almost 1 min on the rotarod compared to the PBS-injected control group; in the hang wire test, mice injected with CBE normally fell off the wire within 10 seconds, due to difficulties using their hind limbs to hold on to the wire. The manual catwalk test demonstrated an increase in inter-limb distance of 0.5 cm in the group injected with CBE. Cessation of CBE treatment on day 25 led to no significant improvement in any of these parameters by day 35 or day 48, although, importantly, no deterioration in the behavioral parameters was detected
The other two groups of mice were injected with CBE for longer period (days [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] and allowed to recover for a longer time (up to day 74) ( (Fig. 6C) , and even after cessation of CBE treatment, mice continued to deteriorate, exhibiting almost zero latency in the rotarod test and inability to hold on to the wire in the hang wire test, due to limb paralysis.
Discussion
In the current study, we have systematically characterized the use of CBE to induce GD in mice. The availability of a chemical inhibitor of GCase should, in principle, allow indepth study of GD development in animal models, and should render GD more accessible to
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experimental manipulation than almost all other LSDs, for which chemical inhibitors of the defective lysosomal enzymes are not readily available. Moreover, the enigmatic relationship between GD/nGD and PD is amenable to study using CBE. Although all the above statements appear axiomatic, the lack of methodical study of the dose, time of injection, levels of accumulation and comparison with genetic models of nGD has often led to skepticism regarding the suitability of CBE as a tool to induce GD/nGD, which the current study seeks to alleviate.
Unsurprisingly, we first showed that the amount of CBE injected into mice directly affects the course of development of GD pathology. However, injection of the same dose of CBE into 15-day-old mice resulted in far less severe pathology than in mice injected from day 8, suggesting that (i) the blood-brain barrier prevents CBE entry in older mice (30, 31) , (ii)
that CBE is less efficient in inhibiting GCase in older mice, (iii) that the brain is less sensitive to GlcCer accumulation in older mice, or (iv) that different levels of GlcCer synthesis in younger vs. older mice could affect the efficacy of CBE. Irrespective of the precise reason for this age-dependent change, the use of higher doses (Table 1) of CBE in older mice is thus justified.
The linear increase in levels of GlcCer and GlcSph accumulation upon increasing amounts of CBE is not surprising, but nevertheless supports the concept that disease severity is directly related to levels of substrate accumulation. Comparison of levels of GlcCer and GlcSph accumulation in mouse models compared to human patients is difficult, due to different methods of measurement, different units often used for quantification and large variability between different human samples, which might be related to parameters such as tissue storage post mortem (Table 4) .
It should be stressed that a number of studies have injected relatively high amounts (100 mg/kg) of CBE into mice, such as those to examine the relationship between PD and
GD. While these studies have uncovered important findings, such as accumulation of α-synuclein, neurodegeneration and gliosis (32, 33) , it should be noted that most GD patients have residual levels of GCase activity, and GD carriers with a higher susceptibility to develop PD have GCase activity in the range of ~50% of normal; we therefore suggest that although more time-consuming, a better way to study the GD/PD connection might be injection of low doses of CBE (<25 mg/kg) for longer periods of time, whereas the higher concentrations (>50 mg/kg) might be better suited for studying the acute forms of nGD. However, it should be noted that in general a larger variability in the phenotype of mice was observed when using lower doses of CBE, necessitating use of a larger group of mice, that should preferably be littermates with similar weights at the beginning of the injection period.
A previous concern using CBE was that it might not fully mimic the pathology observed in genetic models of GD or in human nGD patients. The reasons for this concern were three-fold. First, CBE might have off-target effects, i.e. inhibit other enzymes, which could influence pathology. Second, the penetration, or lack of penetration of CBE across the BBB might result in different patterns of brain pathology from those observed in genetic models. Third, induction of an LSD by chemical inhibition might miss changes that are due to the unfolded proteins often caused by amino-acid substitutions in GCase (34) .
Although the first concern cannot be completely excluded, it is noticeable that many earlier studies reporting off-target effects of CBE in animal models used extremely high doses (sometimes as high as 300 mg/kg (35)). In vitro studies have shown that CBE can inhibit other enzymes such as GBA2, an extra-lysosomal GCase (36), but with lower affinity than GBA1 and at a much lower rate (37) . CBE has also been shown to inhibit some retaining α-glucosidases (38) and lactase-phlorizin hydrolase (39) . We conclude that although CBE might have minor off-target effects, few if any of these are likely to be responsible for the pathology observed, particularly using low levels of CBE. This does not alleviate the need to produce This article is protected by copyright. All rights reserved.
better and more specific GCase inhibitors (40) , but currently CBE is the cheapest and best commercially-available inhibitor. Finally, off-target effects of CBE could be further ruled out by treating Gba flox/flox ;nestin-Cre mice with CBE.
The second concern, that CBE might not mimic GD pathology, can also be alleviated by the current study, in which we show a remarkable overlap in gene profile changes after CBE injection, compared to Gba flox/flox ;nestin-Cre mice, and a rather similar pattern of brain pathology. This is particularly true when comparing the low dose of CBE with the Gba flox/flox ;nestin-Cre mice, although more severe brain pathology was seen in K14-lnl/lnl mice, which itself is not surprising based on the severity of the latter; presumably, a more severe pattern of pathology would be observed using a higher dose of CBE, although this is not something that we directly analyzed. It should also be noted that the regional pathology is somewhat similar to that in the few human brain samples that have been systematically analyzed. Thus, our current study negates to a large extent concerns that CBE does not cause similar pathological changes as in genetic models or in human patients.
The third concern, that CBE is a chemical inhibitor rather than mimicking the effect of unfolded, mutated proteins, is less tractable. However, mice treated with CBE do develop classical GD/nGD symptom, though whether a small subset of symptoms do not develop which might be induced by the unfolded protein response, cannot be excluded.
Having validated the use of CBE as a genuine tool to induce GD/nGD symptoms, we then further demonstrated the usefulness of this model by using it to tease out the temporal sequence of events that result in neuronal cell loss, astrogliosis and microgliosis; this is not possible using either the Gba flox/flox ;nestin-Cre or K14-lnl/lnl mice due to the rapid pathological progression in these mice. Moreover, cessation of CBE injection can be used to determine which symptoms are reversible, and which are not. Finally, a major advantage of the use of CBE is examination of the role of specific biochemical pathways in GD pathology, This article is protected by copyright. All rights reserved.
as exemplified in our recent study showing a role for the Ripk pathway in nGD pathology (6), since CBE can be injected into mice defective in components of putative pathological pathways without the need for time-consuming crossing of mice. CBE can also be used in the study of other putative therapies, such as gene therapy (41), substrate reduction therapy (42), and for the study of biomarkers (28) .
In summary, we have shown that, although it has some limitations, CBE provides an attractive and easy way to induce Gaucher disease in mice, which mimics to a large extent that which is observed in the two available mouse models that mimic neurological forms of GD. 
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